ABP-6016

ABP-6016 is an oral small-molecule drug candidate from Atom Therapeutics (also referred to as Atom Bioscience) being developed for metabolic liver diseases, primarily nonalcoholic steatohepatitis (NASH), now more broadly termed metabolic dysfunction-associated steatohepatitis (MASH), and has also been investigated preclinically for chronic hepatitis B.[1][3][7][11][12][13] Preclinical data cited by the company and secondary intelligence sources indicate that ABP-6016 has shown high potency and an apparently favorable safety profile in NASH/MASH models, but its precise molecular target and mechanism of action have not been publicly disclosed.[1][3][11][12][13] The project has reached preclinical-stage development with its highest reported global status listed as discontinued in public pipeline databases, suggesting that active development may have been halted or deprioritized in favor of other Atom assets.[3][14]